Thorsten Schmidt

Thorsten Schmidt

Auto-generated profile, based on publicly available information

Thorsten Schmidt

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DWDaniel Weishäupl
Daniel Weishäupl
JSJuliane Schneider
Juliane Schneider
BPBarbara Peixoto Pinheiro
Barbara Peixoto Pinheiro
CRCorinna Ruess
Corinna Ruess
SDSandra Maria Dold
Sandra Maria Dold
TSThorsten Schmidt
Thorsten Schmidt
Ataxin-3 is a deubiquitinating enzyme and the affected protein in the neurodegenerative disorder Machado-Joseph disease (MJD). The ATXN3 gene is alternatively spliced, resulting in protein isoforms that differ in the number of ubiquitin-interacting motifs. Additionally, non-synonymous single nucleotide polymorphisms in ATXN3 cause amino acid changes in ataxin-3 and one of these polymorphisms introduces a premature stop codon in one isoform. Here, we examined the effects of different ataxin-3 isoforms and of the premature stop codon on ataxin-3’s physiological function and on main disease mechanisms. At the physiological level, we show that alternative splicing and the premature stop codon alter ataxin-3 stability and that ataxin-3 isoforms differ in their enzymatic deubiquitination activity, subcellular distribution and interaction with other proteins. At the pathological level, we found that the expansion of the polyglutamine repeat leads to a stabilization of ataxin-3 and that ataxin-3 isoforms differ in their aggregation properties. Interestingly, we observed a functional interaction between normal and polyglutamine-expanded ATXN3 allelic variants. We found that interactions between different ATXN3 allelic variants modify the physiological and pathophysiological properties of ataxin-3. Our findings indicate that alternative splicing and interactions between different ataxin-3 isoforms affect not only major aspects of ataxin-3 function but also MJD pathogenesis. Our results stress the importance of considering isoforms of disease causing proteins and their interplay with the normal allelic variant as disease modifiers in MJD and autosomal-dominantly inherited diseases in general.

23 February 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ASAnna Sergeevna Sowa
Anna Sergeevna Sowa
EMElodie Martin
Elodie Martin
IMInês Morgado Martins
Inês Morgado Martins
JSJana Schmidt
Jana Schmidt
RDReinhard Depping
Reinhard Depping
TSThorsten Schmidt
Thorsten Schmidt
Significance: Ataxin-3 is the affected protein in the neurodegenerative disorder spinocerebellar ataxia type 3 (SCA3). Nuclear ataxin-3 has been linked to disease progression and formation of aggregates. Our present findings implicate karyopherin alpha 3 (KPNA3) in the in vitro transport of ataxin-3 and in the SCA3-related phenotypes inDrosophilaand mouse models. We have demonstrated that altering transport proteins has an effect on both pathogenic mechanisms (e.g., the intracellular localization and the formation of aggregates) and key features of ataxin-3 toxicity such as anxiety, total activity, and gait abnormalities. A better appreciation of this cellular mechanism can enhance our understanding of polyglutamine diseases and the role of nuclear/cytoplasmic compartments in toxicity and clearance of ataxin-3.

1 November 2009 in Neurobiology of Disease
Verified
Journal Article
Closed access
PAPaul Antony
Paul Antony
SMSimone Mäntele
Simone Mäntele
PMPhillip Mollenkopf
Phillip Mollenkopf
JBJana Boy
Jana Boy
RKRalph Kehlenbach
Ralph Kehlenbach
TSThorsten Schmidt
Thorsten Schmidt

21 June 2016 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
JSJana Schmidt
Jana Schmidt
TSThorsten Schmidt
Thorsten Schmidt
MGMatthias Golla
Matthias Golla
LLLisa Lehmann
Lisa Lehmann
Jonasz Jeremiasz WeberJonasz Jeremiasz Weber
Jonasz Jeremiasz Weber
OROlaf Riess
Olaf Riess

6 February 2025 in Brain
Verified
Journal Article
Open access
ACAxel Chemla
Axel Chemla
GAGiuseppe Arena
Giuseppe Arena
GSGinevra Sacripanti
Ginevra Sacripanti
KBKyriaki Barmpa
Kyriaki Barmpa
AZAlise Zagare
Alise Zagare
CSClaudia Saraiva
Claudia Saraiva
The complex and heterogeneous nature of Parkinson's disease (PD) is still not fully understood. However, increasing evidence supports mitochondrial impairment as a major driver of neurodegeneration. Miro1, a mitochondrial GTPase encoded by the RHOT1 gene, is involved in mitochondrial transport, mitophagy and mitochondrial calcium buffering, and is therefore essential for maintaining mitochondrial homeostasis. Recently, Miro1 has been linked genetically and pathophysiologically to PD, further supported by the identification of heterozygous variants of Miro1 in patients. Herein, we used patient-derived cellular models alongside knock-in mice to investigate Miro1-dependent pathophysiological processes and molecular mechanisms underlying neurodegeneration in PD. Experimental work performed in induced pluripotent stem cell (iPSC)-derived models, including midbrain organoids and dopaminergic neuronal cell cultures from a PD patient carrying the p.R272Q Miro1 mutation as well as healthy and isogenic controls, indicated that the p.R272Q Miro1 mutation leads to increased oxidative stress, disrupted mitochondrial bioenergetics and altered cellular metabolism. These changes were accompanied by increased α-synuclein levels and a significant reduction of dopaminergic neurons. Moreover, the p.R272Q Miro1 mutation—located in the calcium-binding domain of the GTPase—disrupted calcium homeostasis, resulting in calcium-dependent activation of calpain proteases and the subsequent cleavage of α-synuclein. Knock-in mice expressing p.R285Q Miro1 (the murine orthologue of the human p.R272Q mutation) displayed accumulation of phosphorylated α-synuclein in the striatum and a significant loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by behavioural alterations. These findings demonstrate that mutant Miro1 is sufficient to comprehensively model PD-relevant phenotypes in vitro and in vivo, reinforcing its pivotal role in PD pathogenesis.

1 August 2001 in Molecular Brain Research
Verified
Journal Article
Closed access
Carsten HolzmannCarsten Holzmann
Carsten Holzmann
TSThorsten Schmidt
Thorsten Schmidt
GTGerald Thiel
Gerald Thiel
JEJörg T Epplen
Jörg T Epplen
OROlaf Riess
Olaf Riess